13 August 2015 -  Below is a list of forthcoming submissions that have recently been added to the SMC's programme.

• Atomoxetine hydrochloride (Stattera)
• Dulaglutide (Trulicity)
• Fulvestrant (Faslodex)
• Gefitinib (Iressa)
• Glatiramer acetate (Copaxone)
• Naloxegol oxalate (Moventig)
• Netupitant with palonosetron (Akynzeo)
• Oritavancin diphosphate Orbactiv)
• Sorafenib tosylate (Nexavar)

For more details, go to: http://www.scottishmedicines.org.uk/SMC_Advice/Forthcoming_Submissions/Forthcoming_Submissions?iru=2ICSSBDQBC